Rockville, MD. Rise Therapeutics announced today that they have moved to an Alexandria Real Estate Equities, Inc. (ARE) facility that provides a larger, more effective lab space located in the ARE Maryland life science companies cluster. The mixed laboratory/office space leased by Rise Therapeutics is part of a state-of-the-art research support facility Class A office/lab building located in Rockville, Maryland.
Rockville, MD. Rise Therapeutics today announced that the Montgomery County Economic Development Fund’s subprogram, the SBIR/STTR Matching Grant Program, issued Rise Therapeutics a $25,000 matching grant to further their research project efforts in enhancing the effectiveness of immunotherapy in patients suffering from inflammatory bowel disease (IBD).
Rockville, MD. Rise Therapeutics announced today it was awarded a $2 million, multi-year grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program through the National Institute of Dental and Craniofacial Research (NIDCR). Grant funds will be used to develop a novel, immunologically enhanced probiotic-based therapeutic for the treatment of Sjögren’s syndrome (SS).
Rockville, MD. Rise Therapeutics today announced that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded a three-year Small Business Innovation Research (SBIR) grant to fund the development of the novel engineered probiotic for the treatment of inflammatory bowel disease (IBD).This project builds on the research of co-collaborators Dr. Bikash Sahay and Dr. Ellen Zimmermann at The University of Florida.
Rockville, MD. Rise Therapeutics today announced that the U.S. Patent Trademark Office issued a U.S. patent, No. 9,931,390, entitled “Recombinant Lactococcus Lactis expressing Escherichia Coli Colonization Factor Antigen I (CFA/I) Fimbriae and Their Methods of Use.” The patent covers a first-in-class design related to a platform approach to deliver targeted protein therapies orally. This approach can be used to treat a variety of disease indications.
Rockville, MD. Rise Therapeutics announced today they received their first Small Business Innovation Research (SBIR) Grant from the National of the National Institute of Health (NIH) for their application, “A Novel Probiotic for Preventing and Treating Clostridium Difficile Pathogenesis.” This award signals a significant milestone for Rise Therapeutics and provides a solid foundation for the future of the company.